
PASG Valuation
Passage Bio Inc
- Overview
- Forecast
- Valuation
PASG Relative Valuation
PASG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PASG is overvalued; if below, it's undervalued.
Historical Valuation

No Data
Competitors Valuation Multiple
The average P/S ratio for PASG's competitors is 1.93, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch

TSLA
Tesla Inc
341.930
USD
-2.30%

NVDA
NVIDIA Corp
135.490
USD
+0.07%

AVGO
Broadcom Inc
230.610
USD
+0.87%

XOM
Exxon Mobil Corp
106.470
USD
-1.59%

ORCL
Oracle Corp
159.640
USD
-0.53%

WMT
Walmart Inc
98.120
USD
-0.12%

META
Meta Platforms Inc
640.250
USD
-0.01%

AMZN
Amazon.com Inc
206.140
USD
+0.27%

MSFT
Microsoft Corp
458.860
USD
+1.01%

AAPL
Apple Inc
208.760
USD
-1.18%
FAQ

Is Passage Bio Inc (PASG) currently overvalued or undervalued?
Passage Bio Inc (PASG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1.63. The fair price of Passage Bio Inc (PASG) is between to according to relative valuation methord.

What is Passage Bio Inc (PASG) fair value?

How does PASG's valuation metrics compare to the industry average?

What is the current P/B ratio for Passage Bio Inc (PASG) as of May 19 2025?

What is the current FCF Yield for Passage Bio Inc (PASG) as of May 19 2025?

What is the current Forward P/E ratio for Passage Bio Inc (PASG) as of May 19 2025?
